Financial Contrast: Viridian Therapeutics (NASDAQ:VRDN) and HH&L Acquisition (NYSE:HHLA)

HH&L Acquisition (NYSE:HHLAGet Rating) and Viridian Therapeutics (NASDAQ:VRDNGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.


This table compares HH&L Acquisition and Viridian Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
HH&L Acquisition N/A -55.99% 2.76%
Viridian Therapeutics -10,419.10% -89.08% -48.13%

Earnings and Valuation

This table compares HH&L Acquisition and Viridian Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HH&L Acquisition N/A N/A $17.69 million $0.19 54.90
Viridian Therapeutics $1.77 million 606.26 -$129.87 million ($4.66) -5.34

HH&L Acquisition has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than HH&L Acquisition, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.1% of HH&L Acquisition shares are owned by institutional investors. 0.4% of HH&L Acquisition shares are owned by company insiders. Comparatively, 4.5% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

HH&L Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for HH&L Acquisition and Viridian Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HH&L Acquisition 0 0 0 0 N/A
Viridian Therapeutics 0 0 11 0 3.00

Viridian Therapeutics has a consensus target price of $45.08, indicating a potential upside of 81.18%. Given Viridian Therapeutics’ higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than HH&L Acquisition.


HH&L Acquisition beats Viridian Therapeutics on 7 of the 12 factors compared between the two stocks.

About HH&L Acquisition

(Get Rating)

HH&L Acquisition Co. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on healthcare or healthcare-related companies in Asian markets. The company was incorporated in 2020 and is based in Central, Hong Kong.

About Viridian Therapeutics

(Get Rating)

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Receive News & Ratings for HH&L Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HH&L Acquisition and related companies with's FREE daily email newsletter.